MAURA KENNEY- KIERAN: Open Payments
NPI 1376549725 · ROSLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$475 in 24 payments from 10 companies in 2025. Trend: 2023 $886 · 2024 $623 · 2025 $475
Food & beverage: $475
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 7 | $120 |
| AstraZeneca Pharmaceuticals LP | 3 | $69 |
| Amgen Inc. | 3 | $65 |
| Merck Sharp & Dohme LLC | 3 | $49 |
| E.R. Squibb & Sons, L.L.C. | 2 | $44 |
| Novo Nordisk Inc | 2 | $40 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Chiesi USA, Inc. | 1 | $23 |
| PFIZER INC. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $16 |
Products named: LEQVIO, FARXIGA, REPATHA, VERQUVO, ELIQUIS, AMVUTTRA, CAMZYOS, CLEVIPREX.
Industry payments across NY — which companies pay providers there.
